Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02270619 · ClinicalTrials.gov registry record · Early Phase 1
Sleep Health, Inflammation, and Emotion Study
A Early Phase 1 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 95
- Enrollment target
NCT02270619: Completed Early Phase 1 study, sponsored by University of California, Los Angeles.
NCT02270619 is a Early Phase 1 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 95 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (79% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02270619, a Early Phase 1 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
Late-life depression is a major public health burden due to its high prevalence and associated morbidity, suicide risk, functional decline, and mortality. Unfortunately, current antidepressant therapies have limited effectiveness; hence, biologically plausible models for new treatments are being pursued. Systemic inflammation is hypothesized to play an important role on the onset and perpetuation of depression, especially in older women. Aging processes involve a heightened inflammatory state, and both inflammatory disorders and depression are more prevalent in women than men. However, increased systemic inflammation does not necessarily lead to depression in all women. Even when robust systemic inflammation is experimentally induced (e.g. endotoxin administration), largely variable increases in depressive symptoms are found. Defining the factors that account for this variability may identify individuals at risk of developing depression when exposed to heightened inflammatory states such as aging, obesity, and chronic disease, and informs future translational studies of depression prevention. In particular, the role of sleep disturbance in explaining this variability requires further attention because it is an independent risk factor for depression and heightens systemic inflammation by increasing the production of proinflammatory cytokines. The investigators have also discovered that women, but not men, who report sleep disturbance including short sleep duration experience significantly more depressive symptoms in response to an inflammatory challenge than women without sleep disturbance. Thus, it is hypothesized that sleep loss is a vulnerability factor for inflammation-induced depressive symptoms in women. However, to date, no experimental approach has been used to evaluate the role of sleep loss on inflammation-induced depressive symptoms. This proposal aims to examine this hypothesis by partial sleep deprivation (PSD) followed by endotoxin challenge in older wo
Primary Outcome
Short Form of the Profile of Mood States (POMS-SF)
Interventions
- OTHER Placebo
- BIOLOGICAL Endotoxin
- BEHAVIORAL Partial sleep deprivation
- OTHER Uninterrupted sleep
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2014-10 |
| Est. Completion | 2021-01 |
| Phase | Early Phase 1 |
What the finished NCT02270619 record still lists
NCT02270619 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (79% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02270619 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02270619 about?
NCT02270619 is a clinical study titled "Sleep Health, Inflammation, and Emotion Study". Late-life depression is a major public health burden due to its high prevalence and associated morbidity, suicide risk, functional decline, and mortality. Unfortunately, current antidepressant therapies have limited effectiveness; hence, biologically plausible models for new treatments are being pur...
What is the current status of trial NCT02270619?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 95 participants. The study started on 2014-10. Estimated completion is 2021-01.
What interventions are being tested in trial NCT02270619?
The interventions under investigation include: Placebo (OTHER), Endotoxin (BIOLOGICAL), Partial sleep deprivation (BEHAVIORAL), Uninterrupted sleep (OTHER).
Who is sponsoring clinical trial NCT02270619?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02270619's enrollment target sits among peer trials
95 226th of 2000 higher than 1,774 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia